Johnson & Johnson's Fiscal Year is From January To December - All Figures are in USD, Billions.
The item "Operating-Expenses" stands at 38.69 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.
Johnson & Johnson's third quarter result of 9.59 Billion USD for the item "Operating Expenses" represents an increase of 3.11 percent compared to it's second quarter result.
Also, Johnson & Johnson's third quarter result of 9.59 Billion USD for the item "Operating Expenses" represents a decrease of -6.22 percent compared to it's third quarter result of last year.
Looking again at the trailing twelve months series (TTM), Johnson & Johnson's third quarter result of 38.69 Billion USD for the item "Operating Expenses" represents a decrease of -1.62 percent compared to it's second quarter result.
Regarding the One-Year-Change of the series, the current value constitutes an increase of 2.51 percent compared to the value the year prior.
The 1 year change in percent is 2.51.
The 3 year change in percent is -7.61.
The 5 year change in percent is 17.86.
The 10 year change in percent is 29.17.
| Logo | Name | Market Cap (USD) |
|---|---|---|
![]() | Eli Lilly and Company - Operating Expenses | 905,699,262,464.00 |
![]() | AbbVie Inc - Operating Expenses | 399,570,305,024.00 |
![]() | Roche Holding AG - Operating Expenses | 317,433,206,677.55 |
![]() | AstraZeneca PLC - Operating Expenses | 280,205,508,085.11 |
![]() | Novartis AG - Operating Expenses | 255,096,620,580.91 |